Pharma Sources Insight第四期：复盘抗疫之年，破局产业未来

https://www.cphi.cn 2021-02-02 10:16 来源：CPhI制药在线

本期Pharma Sources Insight将与制药人士一起复盘，盘点2020年**行业、生物类似药、国产生物药的发展及GMP监管趋势。

进入2021，观其形势，疫情将继续在全球范围内受到普遍关注，过去一年，疫情对制药行业的影响几何？中国及全球**研发究竟到了怎样的阶段？随着**的到来，制药行业未来的发展又将导向何方？

站在新的起点，本期Pharma Sources Insight将与制药人士一起复盘，盘点2020年**行业、生物类似药、国产生物药的发展及GMP监管趋势；同时立足药物研发的前沿，探索2021年制药行业在肿瘤**、人工智能等领域的潜在发展方向，使世界专业人士更了解中国的药物审批与药企发展状况，为药企未来的发展注入新的活力。

本期内容也将向您展示与CPhI制药在线合作的品质供应商，同时也是CPhI & P-MEC China的展商所带来的特色产品——浙江江北药业有限公司的原料药产品，以及上海东富龙科技股份有限公司的无菌溶媒结晶原料药系统。PharmaSources.com始终致力于向国际市场推介中国本土合作伙伴提供的解决方案，帮助业内人士在抗疫之年，降低采购成本，满足企业采购需求。

新的一年，作为制药行业专业的垂直型B2B贸易平台，PharmaSources.com将秉持诚意集结制药行业内资深的新作者，提供更高品质的原创内容，打破疫情时期国际贸易的障碍，赋能制药行业向纵深发展。欢迎有意向携手制药在线国际站PharmaSources.com及Pharma Sources Insight进行品牌推广的企业，留言咨询合作详情。

Pharma Sources Insight

January 2021

Pharma Sources Insight is a unique source of updated coverages on current events and deep insights into hot areas of the pharma industry, from China to the world. It follows up new developments with the leading drug-manufacturers in China which further affect the world.

Now, join PharmaSources.com to get access to news of the Chinese pharmaceutical enterprises and to witness industrial changes through the exclusive perspectives of our expert writers into crucial aspects of the pharmaceutical field, all under PharmaSources.com and CPhI China.

Contents：

Pharma Sources Insight January 2021 focuses on the following topics:

PHARMA IN CHINA

- Analysis of the Regulatory Inspection Trends of China, the U.S. and the EU in the Pandemic Year and Outlook Therefor

- Chinese-produced Anticancer Drugs Granted Designations by the FDA in 2020

- A Brief Preview of 2021 in the Pharmaceutical Industry

COVID-19

- A Brief Overview of COVID-19 Pandemic in 2020

- Chinese Vaccines Going Global amid Receipt of the COVID-19 Vaccines Worldwide

- Notable Vaccines Against COVID-19 Making Promising Progress

- Rolling Out the Vaccines

Brand Story